Skip to main content
Premium Trial:

Request an Annual Quote

BioFocus, Almac Partner to Offer Screening, Profiling Services

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – BioFocus and Almac today announced a deal to provide compound screening and profiling services based on Almac's Flexyte fluorescence lifetime assays to BioFocus' customers.

BioFocus has launched an FLT screening and profiling service using the Flexyte assay platform and is offering services against targets such as proteases, phosphatases, and kinases.

"The unique properties of FLT have also been harnessed to open up access to previously inaccessible epigenetics target classes," the firms said in a joint statement.

Approaches that can be used on the Flexyte platform include fragment-based screens and kinetic profiling, they added.

Financial and other terms of the deal were not disclosed.

Almac is a Craigavon, Northern Ireland-based drug development services firm. UK-based BioFocus is the drug discovery services division of Galapagos.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.